Halozyme Therapeutics Inc. Common Stock vs Veeva Systems — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.89 (market cap $12.58B), while Veeva Systems trades at $287.84 (market cap $46.12B). The key difference: Veeva Systems is far larger — about 3.7× Halozyme Therapeutics Inc. Common Stock's market cap, and Veeva Systems is more actively traded (921,537 versus 2,179,278). Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Veeva Systems for 5 Days on average.
| HALO | VEEV | |
|---|---|---|
Market Cap | $12.58B | $46.12B |
Volume | 2,179,278 | 921,537 |
Sector | Health | Technology |
52-Week High | $115.22 | $299.10 |
52-Week Low | $61.63 | $151.43 |
Typical Hold Time | 0 Days | 5 Days |
Enterprise Value | $14.49B | $39.03B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →Veeva Systems provides cloud software, data, and services for the life sciences industry. Its applications support functions across clinical research, regulatory operations, quality, safety, and commercial teams.
Read more on VEEV →